Studies have shown that SGLT-2 inhibitors reduce the risk of major adverse cardiovascular events, hospitalization for heart failure, and the progression of CKD [96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111]. This evidence concerns the gene SLC5A2 and chronic kidney disease.